



Prof. Claudio Rivera
Project Lead

Anastasia Ludwig, PhD
Lead Scientist

Pavel Uvarov, PhD
Researcher

Minna Launiainen, MSc
Researcher

Svetlana Sharifulina, PhD
Commercial Lead

50M

People with epilepsy

1 in 3

Drug-resistant

€16.4B

Market size by 2034

€2B/yr

Potential savings

Stop Seizures | R2B Project

Safe drug for acute seizures with rapid onset that can be administered subcutaneously outside of medical settings

Application

- Novel drug XlorAid targets neuronal ion transporter KCC2 that plays a key role in seizure
- Scalable potential across KCC2-related neurological disorders

Market assessment

- €328M entry market (US & EU)
- €12B total addressable market
- Expansion into KCC2-related neurological conditions or other KCC2-related diseases.

Competitive advantages

- First-in-class KCC2 mechanism
- Root cause approach
- Selective neuronal activity
- Favorable safety profile
- Rapid, out-of-hospital delivery

IP Status

- Patent in preparation + in-vivo proof-of-concept
- Strong foundation for pharma co-development or spin-off

Needs

We are seeking strategic investment to advance XlorAid into clinical development (IND-enabling stage).

Project Lead

Prof. Claudio Rivera
claudio.rivera@helsinki.fi

Commercial Lead

Svetlana Sharifulina, PhD
svetlana.sharifulina@helsinki.fi

The team

- Anastasia Ludwig, PhD, Lead scientist
- Pavel Uvarov, PhD
- Minna Launiainen, MSc



Contact us on LinkedIn

